Start/CVS

Public research page

Market data comes from the live feed. The company research below uses verified public sources, but it is not a real-time personalized AI conclusion.

Analyze CVS in workspace
CVSNYSE/health care

CVS Health Corporation

$105.90Up+1,75 (+1,68%)
Research reviewed: 12. Juli 2026, 00:00 UTC
Research overview3-month price contextInvestment thesisKey catalystsLatest earnings researchRecent newsData and research sources

Research overview

CVS Health Corporation operates in Health Care Services within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Eröffnung
105,00
Hoch
106,40
Tief
104,62
Marktkapitalisierung
135,12 Mrd.
KGV
46.45
52-Wochen-Hoch
--
Dividende
2.550%
Quartalsdividende
--

3-month price context

Das Chart zeigt den jüngsten 3-Monats-Trend, damit Nutzer die kurzfristige Struktur verstehen können, bevor sie den vollen Workspace öffnen.

Investment thesis

Base case
Pricing, benefit redesign and membership actions can improve alignment between premiums and medical costs. The base case remains conditional on medical-cost trend staying manageable.
Bull case
Pricing, benefit redesign and membership actions can improve alignment between premiums and medical costs. Insurance, PBM, pharmacy and care-delivery assets can coordinate access and lower total care costs. Retail and specialty pharmacy scale can support purchasing economics and recurring prescription relationships.
Bear case
Higher utilization or acuity can outpace pricing and pressure insurance margins. Rebate, transparency and pharmacy-reimbursement reforms could alter Caremark economics. Leverage and complexity across acquired care assets can limit capital flexibility and delay returns.

Key catalysts

  • Aetna margin recovery

    Pricing, benefit redesign and membership actions can improve alignment between premiums and medical costs.

  • Integrated care model

    Insurance, PBM, pharmacy and care-delivery assets can coordinate access and lower total care costs.

  • Pharmacy scale

    Retail and specialty pharmacy scale can support purchasing economics and recurring prescription relationships.

Principal risks

  • Medical-cost trend

    Higher utilization or acuity can outpace pricing and pressure insurance margins.

  • PBM regulation

    Rebate, transparency and pharmacy-reimbursement reforms could alter Caremark economics.

  • Debt and execution

    Leverage and complexity across acquired care assets can limit capital flexibility and delay returns.

Latest earnings research

Q1 2026

CVS Health's first-quarter 2026 update reflected progress in the Aetna insurance recovery, continued pharmacy and PBM scale and an ongoing effort to simplify health-services operations while managing elevated medical costs.

Valuation interpretation

  • A recovery interpretation depends on sustained insurance repricing rather than a short-lived moderation in medical utilization.
  • Integrated-health optionality should be balanced against PBM policy risk, leverage and operational complexity.

Peer research

ABBVJNJLLY

Recent news

Trefis · vor 8 Stunden

The Premium On CVS Stock Vs What Its Peers Deliver

Zacks · vor 9 Stunden

Humana Eyes 3% Medicare Advantage Margin: Can It Deliver?

Insider Monkey · vor 11 Stunden

Jim Cramer Says “Buy the Stock of CVS, I Sure Wish I’d Done It for My Trust”

Barrons.com · vor 19 Stunden

Elevance and UnitedHealth Earnings Are Next Test for Hot Health Insurer Stocks

Motley Fool · vor 3 Tagen

2 Recession-Resistant Dividend Stocks to Buy and Hold

Continue in the research workspace

Keep CVS in context, run a multi-agent analysis, and monitor thesis changes.

Analyze CVS free

Das gesamte Research-System erkunden

Jede Phase erfüllt eine klare Aufgabe und hinterlässt ein prüfbares Ergebnis.

AnalysemethodikMarktberichte lesen
Thesis invalidation
Reassess the thesis if higher utilization or acuity can outpace pricing and pressure insurance margins.

Zacks · vor 3 Tagen

Brookdale Senior Q2'26 Sneak Peek: Occupancy Volume Rises to 82.4%

Data and research sources

Research updated: 12. Juli 2026, 00:00 UTC
3 verified sources
CVS Health Reports First Quarter 2026 ResultsCVS Health Corporation · earningsVerified

Fetched: 12.7.2026, 0:00:00 UTC

Published: 6.5.2026, 00:00:00

Open original source
CVS Health Corporation Investor RelationsCVS Health Corporation · companyVerified

Fetched: 12.7.2026, 0:00:00 UTC

Open original source
CVS Health SEC filings and company factsU.S. Securities and Exchange Commission · filingVerified

Fetched: 12.7.2026, 0:00:00 UTC

Published: 6.5.2026, 00:00:00

Open original source
Aktien erkunden

Continue researching this stock

Marktanalyst

Marktanalyst fokussiert sich innerhalb von Kernresearch auf die Phase Beobachten und bereitet den Kontext für nachgelagerte Rollen vor.

Fundamentalanalyst

Fundamentalanalyst fokussiert sich innerhalb von Kernresearch auf die Phase Beobachten und bereitet den Kontext für nachgelagerte Rollen vor.

Nachrichtenanalyst

Nachrichtenanalyst fokussiert sich innerhalb von Kernresearch auf die Phase Beobachten und bereitet den Kontext für nachgelagerte Rollen vor.

Risikomanager

Risikomanager fokussiert sich innerhalb von Risiko und Monitoring auf die Phase Überwachen und bereitet den Kontext für nachgelagerte Rollen vor.